Skip to Content

Dear Customer:

The current international situation is complex and volatile, and uncertain tariff policies may potentially impact our product prices. Given these uncertainties, we value your understanding regarding order-related matters.

If you decide to place an order during this period, we reserve the right to adjust the price based on the evolving situation. We understand that market changes may cause inconvenience. We will negotiate with you if there’s a significant price fluctuation due to tariff policy changes before the order’s actual delivery, and in such cases we may adjust or cancel the order as necessary.

We are planning system maintenance between Friday, Apr 18 at 9:00 PM CDT and Saturday, Apr 19 at 9:00 AM CDT. This will impact both web and offline transactions, including online orders, quotes, price and availability checks, and order status inquiries. We apologize for any inconvenience.

For important updates on recent policy changes, please click here for more details.

Merck
CN
  • Clinical results of topography-based customized ablations in highly aberrated eyes and keratoconus/ectasia with cross-linking.

Clinical results of topography-based customized ablations in highly aberrated eyes and keratoconus/ectasia with cross-linking.

Journal of refractive surgery (Thorofare, N.J. : 1995) (2013-03-02)
David T C Lin, Simon Holland, Johnson C H Tan, Gregory Moloney
ABSTRACT

To report results of a series of highly aberrated corneas treated with a topography-guided excimer laser ablation. Retrospective, nonrandomized, consecutive series of eyes treated with topography-guided photorefractive keratectomy (TG-PRK) with the customized topographical neutralization technique (TNT). Cases included postoperative refractive surgery decentered ablations, optical zone enlargement, asymmetrical astigmatism, postoperative radial keratotomy (RK), postoperative keratoplasty, keratoconus combined with collagen cross-linking (CXL), and postoperative LASIK ectasia combined with CXL. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), and manifest refraction were analyzed preoperatively and 6 months postoperatively. In decentered ablation cases, 94% of 37 eyes were within 1.00 diopter (D) of the attempted refractive outcome, with 76% within 0.50 D. Mean topographic, central, optical zone of uniform (monodioptric) power increased from 3.5 to 5.2 mm in 25 eyes. Thirty-one eyes treated for asymmetrical astigmatism showed improvement in cylinder from mean 1.31 to 0.52 D. Ten of 11 eyes treated for previous RK astigmatism achieved postoperative UDVA 20/40 or better. Twenty-seven eyes with postoperative keratoplasty astigmatism were treated, with 7 (25.9%) eyes gaining > or = 2 lines and 12 (44.4%) eyes gaining > or = 1 line of CDVA. Of eyes with keratoconus that were treated using TG-PRK with CXL, 42 (58%) eyes had UDVA 20/40 or better, and 66 (92%) eyes had CDVA 20/40 or better. Twelve (71%) of 17 eyes treated for postoperative LASIK ectasia using TG-PRK with CXL had UDVA 20/40 or better. Nine (53%) eyes gained > or = 2 lines of CDVA. Topography-guided laser treatment with custom TNT, combined with CXL in keratoconus and ectasia, is an effective, safe, and increasingly predictable option for highly aberrated corneas.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
(−)-Riboflavin, meets USP testing specifications
Pricing and availability is not currently available.
Sigma-Aldrich
(−)-Riboflavin, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥98%
Pricing and availability is not currently available.
Sigma-Aldrich
(−)-Riboflavin, from Eremothecium ashbyii, ≥98%
Pricing and availability is not currently available.
Supelco
Riboflavin, Pharmaceutical Secondary Standard; Certified Reference Material
Pricing and availability is not currently available.
Riboflavin, European Pharmacopoeia (EP) Reference Standard
Pricing and availability is not currently available.
Supelco
Riboflavin (B2), analytical standard
Pricing and availability is not currently available.